About Us

Overview

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists in over 100 countries.

IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

The IASLC mission is:

  • to embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies;
  • to provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public;
  • to use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.

The Journal of Thoracic Oncology

The Journal of Thoracic Oncology (JTO) is the IASLC's premier journal. JTO emphasizes a multidisciplinary approach in the articles accepted for publication, and includes original research (clinical trials and translational or basic research), reviews and opinion pieces. Become a member of IASLC and receive a complimentary subscription to the Journal of Thoracic Oncology. Members can login to the IASLC Member Portal to access the journal articles (membership must be current.)

The core audience for the journal includes those involved in the research and treatment of thoracic malignancies including, epidemiologists, medical oncologists, pulmonologists, radiation oncologists, thoracic surgeons, radiologists, pathologists and research scientists.

First published in January of 2006, the journal is a monthly publication. The 2017 Impact Factor was 10.336, up from 6.595 in 2016. JTO was ranked 11 out of 222 for oncology and 4 out of 59 for respiratory system subject matter categories in the 2017 Journal Citation Reports. In 2018, 1,281 original research articles were submitted with acceptance of 141, resulting in an acceptance rate of 11%. For all submission types, there were 1,744 manuscripts submitted and 247 were accepted, equating an acceptance rate of 14.2%. JTO maintains a quick turnaround time of 9.3 days to first decision and an average of 9.5 days for revisions. JTO publishes articles online within 5 days of acceptance. Articles of high scientific interest receive fast track designation, are reviewed within 48 hours, and published online within 3-5 days. Select articles are promoted via social media and press release.

Meet the Editor 

 

Alex A. Adjei, MD, PhD, FACP

Dr. Adjei is Professor of Oncology in the Department of Medicine at Mayo Clinic in Rochester, Minnesota.